FDA Approves TACROLIMUS — Ascend Laboratories, LLC

Ascend Laboratories, LLC has announced the FDA approval of its tacrolimus ANDA, entering the competitive oral tacrolimus market with a potential impact on brand pricing and generic availability. This approval complements the company's existing portfolio and strengthens its position within the immunosuppressant sector, impacting supply chains for high-stakes transplant patients.